Our Product

OMIDRIA® (phenylephrine
and ketorolac intraocular
solution) 1% / 0.3%


OMIDRIA, Omeros’ PharmacoSurgery® product, is a first-of-kind drug approved both in the US and in Europe to prevent miosis in cataract surgery and to reduce postoperative pain. OMIDRIA has been shown to reduce complications, to prevent intraoperative floppy iris syndrome (IFIS), and to reduce the need for opioids, pupil-expansion devices and postoperative steroids.

Learn More
OMIDRIA (phenylephrine and ketorolac intraocular solution) 1% / 0.3%


OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.


OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure of phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.